Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for hypertension
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Blood Pressure and Renal Responses to Orthostatic Stress Before and After Radiofrequency Renal Denervation in Patients with Resistant Hypertension 29876358 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Blood Pressure and Renal Responses to Orthostatic Stress Before and After Radiofrequency Renal Denervation in Patients with Resistant Hypertension. 42 10.3389/fcvm.2018.00042 In patients with resistant hypertension, renal denervation (RDN) studies have (...) ) and after one hour of LBNP at three different time points: before (M0), one (M1) and twelve months (M12) after RDN. Thirteen patients with resistant hypertension were included. In the resting state, no differences were observed in norepinephrine, PRA, sodium excretion and mean BP levels after RDN. GFR (78 ± 32 ml/min at M0 vs 66 ± 26 ml/min at M12 ( p = 0.012) and filtration fraction (22.6 ±5.4% at M0 vs 15.1 ±5.3% at M12 ( p = 0.002)) both decreased after RDN. During LBNP, the magnitude of the mean BP
Pulmonary Hypertension in Aortic and Mitral Valve Disease 29876357 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Pulmonary Hypertension in Aortic and Mitral Valve Disease. 40 10.3389/fcvm.2018.00040 In patients with aortic and/or mitral valve disease the presence of pulmonary hypertension (PH) indicates a decompensated state of the disease with left ventricular and left atrial dysfunction and exhausted compensatory mechanism, i.e., a state of heart (...) failure. Pulmonary hypertension in this context is the consequence of the backwards transmission of elevated left atrial pressure. In this form of PH, pulmonary vascular resistance is initially normal (isolated post-capillary PH). Depending on the extent and chronicity of left atrial pressure elevation additional pulmonary vascular remodeling may occur (combined pre- and post-capillary PH). Mechanical interventions for the correction of valve disease often but not always reduce pulmonary pressures. However
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. BACKGROUND: Early studies suggest that radiofrequency-based renal denervation reduces blood pressure in patients with moderate hypertension. We investigated whether an alternative technology using endovascular ultrasound renal denervation reduces ambulatory blood pressure in patients with hypertension in the absence (...) of antihypertensive medications. METHODS: RADIANCE-HTN SOLO was a multicentre, international, single-blind, randomised, sham-controlled trial done at 21 centres in the USA and 18 in Europe. Patients with combined systolic-diastolic hypertension aged 18-75 years were eligible if they had ambulatory blood pressure greater than or equal to 135/85 mm Hg and less than 170/105 mm Hg after a 4-week discontinuation of up to two antihypertensive medications and had suitable renal artery anatomy. Patients were randomised
A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease 29750141 2018 11 14 2312-0541 4 2 2018 Apr ERJ open research ERJ Open Res A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. 00124-2017 10.1183/23120541.00124-2017 European Respiratory Society (ERS) guidelines recommend the assessment of patients with interstitial lung disease (ILD) and severe (...) pulmonary hypertension (PH), as defined by a mean pulmonary artery pressure (mPAP) ≥35 mmHg at right heart catheterisation (RHC). We developed and validated a stepwise echocardiographic score to detect severe PH using the tricuspid regurgitant velocity and right atrial pressure (right ventricular systolic pressure (RVSP)) and additional echocardiographic signs. Consecutive ILD patients with suspected PH underwent RHC between 2005 and 2015. Receiver operating curve analysis tested the ability
Syncope, Hypotension, and Falls in the Treatment of Hypertension: Results from the Randomized Clinical Systolic Blood Pressure Intervention Trial 29601076 2018 04 18 1532-5415 66 4 2018 Apr Journal of the American Geriatrics Society J Am Geriatr Soc Syncope, Hypotension, and Falls in the Treatment of Hypertension: Results from the Randomized Clinical Systolic Blood Pressure Intervention Trial. 679-686 10.1111/jgs.15236 To determine predictors of serious adverse events (SAEs) involving syncope
Selexipag (Uptravi) - For the long-term treatment of pulmonary arterial hypertension (PAH) Published 7 May 2018 1 Resubmission selexipag, 200 microgram, 400 microgram, 600 microgram, 800 microgram, 1,000 microgram, 1,200 microgram, 1,400 microgram, 1,600 microgram film-coated tablets (Uptravi ® ) SMC No. 1235/17 Actelion Pharmaceuticals Ltd 6 April 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic (...) Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a resubmission assessed under the orphan equivalent process selexipag (Uptravi ® ) is accepted for restricted use within NHS Scotland. Indication under review: For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II to III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA
Ocular Hypertension Ocular hypertension (OHT) submit The College submit You're here: Ocular hypertension (OHT) Ocular hypertension (OHT) The CMGs are guidelines on the diagnosis and management of a range of common and rare, but important, eye conditions that present with varying frequency in primary and first contact care. Share options Aetiology Ocular hypertension (OHT) is defined as consistently elevated intraocular pressure (IOP) (greater than 21mmHg [2 standard deviations above (...) be monitored in the community. Such patients may be advised that they should be reviewed by a community optometrist every 12 months (SIGN recommendation) (GRADE*: Level of evidence=low, Strength of recommendation=strong) Data from the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS) have been used to produce a risk calculator to predict the five-year risk of developing POAG in adult patients with ocular hypertension. All of the variables included
Macitentan in pulmonary hypertension due to left ventricular dysfunction 29437943 2018 02 13 1399-3003 51 2 2018 Feb The European respiratory journal Eur. Respir. J. Macitentan in pulmonary hypertension due to left ventricular dysfunction. 1701886 10.1183/13993003.01886-2017 The MELODY-1 study evaluated macitentan for pulmonary hypertension because of left heart disease (PH-LHD) in patients with combined post- and pre-capillary PH.63 patients with PH-LHD and diastolic pressure gradient ≥7 mmHg
Hypertension and its association with Anthropometric indices among students in a public university 29796204 2018 11 14 1985-207X 13 1 2018 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia Malays Fam Physician Hypertension and its association with Anthropometric indices among students in a public university. 2-9 The present study aimed to determine the prevalence of hypertension and its association with nutritional status (body mass index, body (...) fat percentage, and visceral fat) among students in a public university in Sarawak, Malaysia. This was a cross-sectional study among undergraduate students aged 18 years old and above. Anthropometric measurements, such as weight, height, body composition, and blood pressure measurements, were collected. Hypertension was defined as equal or more than 140/90 mmHg. Statistical analyses were done using IBM SPSS version 20. A total of 354 respondents participated in the study. Mean age
Prevalence of CKD, Diabetes, andÂ Hypertension in Rural Tanzania 29989050 2018 11 14 2468-0249 3 4 2018 Jul Kidney international reports Kidney Int Rep Prevalence of CKD, Diabetes, and Hypertension in Rural Tanzania. 905-915 10.1016/j.ekir.2018.04.006 Chronic kidney disease (CKD), diabetes, and hypertension play a disproportionate role in the growing public health challenge posed by noncommunicable diseases (NCDs) in East Africa. The impact of these NCDs may pose the greatest challenge in rural (...) areas with limited screening and treatment facilities, although precise prevalence estimates of these conditions in rural Tanzania are lacking. The prevalence of CKD, diabetes, and hypertension, were estimated from a probability sample of adults (n = 739) residing in 2 communities within Kisarawe, a rural district of Tanzania. Following consent, participants were studied in their homes. Random point-of-care (POC) measures of glycosylated hemoglobin and blood pressure, were obtained. Serum creatinine
First-line drugs for hypertension. BACKGROUND: This is the first update of a review published in 2009. Sustained moderate to severe elevations in resting blood pressure leads to a critically important clinical question: What class of drug to use first-line? This review attempted to answer that question. OBJECTIVES: To quantify the mortality and morbidity effects from different first-line antihypertensive drug classes: thiazides (low-dose and high-dose), beta-blockers, calcium channel blockers (...) , ACE inhibitors, angiotensin II receptor blockers (ARB), and alpha-blockers, compared to placebo or no treatment.Secondary objectives: when different antihypertensive drug classes are used as the first-line drug, to quantify the blood pressure lowering effect and the rate of withdrawal due to adverse drug effects, compared to placebo or no treatment. SEARCH METHODS: The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials up to November 2017
Spironolactone is effective for treating resistant hypertension NIHR DC | Signal - Spironolactone is effective for treating resistant hypertension Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Spironolactone is effective for treating resistant hypertension Published on 1 December 2015 This trial investigated which drug is best added to high blood pressure (hypertension) treatment if blood pressure has not come down to normal levels after taking three blood pressure lowering (...) drugs. Such “resistant hypertension” accounts for around 10% of all people who have hypertension. The study found that adding spironolactone to the existing three-drug regimen was the most effective treatment and was well-tolerated by patients. Spironolactone is currently recommended by NICE at this fourth stage of treatment, but at half the dose used in this study. The higher dose will increase the cost of prescribing slightly. Potassium levels need to be monitored when using spironolactone
Integrative Bioinformatics Approaches for Identification of Drug Targets in Hypertension 29670885 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Integrative Bioinformatics Approaches for Identification of Drug Targets in Hypertension. 25 10.3389/fcvm.2018.00025 High blood pressure or hypertension is an established risk factor for a myriad of cardiovascular diseases. Genome-wide association studies have successfully found over nine hundred loci (...) that contribute to blood pressure. However, the mechanisms through which these loci contribute to disease are still relatively undetermined as less than 10% of hypertension-associated variants are located in coding regions. Phenotypic cell-type specificity analyses and expression quantitative trait loci show predominant vascular and cardiac tissue involvement for blood pressure-associated variants. Maps of chromosomal conformation and expression quantitative trait loci (eQTL) in critical tissues identified
Social deprivation and prognosis in Scottish patients with pulmonary arterial hypertension 29386345 2018 02 01 1399-3003 51 2 2018 Feb The European respiratory journal Eur. Respir. J. Social deprivation and prognosis in Scottish patients with pulmonary arterial hypertension. 1700444 10.1183/13993003.00444-2017 Several demographic and clinical factors have prognostic significance in idiopathic pulmonary arterial hypertension (IPAH). Studies in China and the USA have suggested an association
Clinical Decision Support for Recognition and Management of Hypertension: A Randomized Trial 29371241 2018 02 17 1098-4275 141 2 2018 Feb Pediatrics Pediatrics Clinical Decision Support for Recognition and Management of Hypertension: A Randomized Trial. e20172954 10.1542/peds.2017-2954 Although blood pressure (BP) is routinely measured in outpatient visits, elevated BP and hypertension are often not recognized. We evaluated whether an electronic health record-linked clinical decision support (...) (CDS) tool could improve the recognition and management of hypertension in adolescents. We randomly assigned 20 primary care clinics within an integrated care system to CDS or usual care. At intervention sites, the CDS displayed BPs and percentiles, identified incident hypertension on the basis of current or previous BPs, and offered tailored order sets. The recognition of hypertension was identified by an automated review of diagnoses and problem lists and a manual review of clinical notes
Relationship between health literacy and knowledge among patients with hypertension in Isfahan province, Iran Relationship between health literacy and knowledge among patients with hypertension in Isfahan province, Iran Search Search... For Authors Research Reporting Guidelines: Selected Editorials , Editorial by Associate Editor Prof. Dr. Umesh Wadgave, India. November 2018 . Editorial by Associate Professor Dr. Hossein Sanaei-Zadeh, Shiraz University of Medical Sciences, Shiraz, Iran. July (...) , Akbar Hasanzadeh, Firoozeh Mostafavi Parent Category: Category: Abstract Background : Hypertension is usually symptomless, and is not seriously attended until it causes some chronic complications. Individuals’ skills in understanding and applying information about health subjects may have a substantial impact on patients’ behavior and health. Objective : to determine the relationship between health literacy and knowledge among patients with hypertension in Isfahan province, Iran. Methods
Comparison of continuousâ€flow ventricular assist device therapy with intensive medical therapy in fixed pulmonary hypertension secondary to advanced left heart failure Comparison of continuous-?ow ventricular assist device therapy with intensive medical therapy in ?xed pulmonary hypertension secondary to advanced left heart failure Gayathri Kumarasinghe 1 , Pankaj Jain 1,2 , Andrew Jabbour 1,2,3 , Jacqueline Lai 1 , Anne M. Keogh 1,2,3 , Eugene Kotlyar 1,2 , Paul Jansz 1 , Peter S. Macdonald (...) 1,2,3 and Christopher S. Hayward 1,2,3 * 1 Heart and Lung Transplant Unit, St. Vincent’s Hospital, Darlinghurst, NSW, Australia; 2 University of New South Wales, Sydney, NSW, Australia; 3 Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia Abstract Aims Bothventricularassistdevice(VAD)andpulmonaryvasodilatortherapyhavebeenshowninuncontrolledstudiestoim- prove pulmonary hypertension secondary to advanced left heart failure (Group 2 PH). This study aimed to compare haemody- namicbene
Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors | European Respiratory Society Main menu User menu Search Search for this keyword Search for this keyword Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors Todd M. Tartavoulle , Aryn C. Karpinski , Andrew Aubin , Benzi M. Kluger , Oliver Distler , Lesley Ann Saketkoo ERJ Open Research (...) , Aurora, CO, USA Oliver Distler Dept of Rheumatology, University Hospital Zurich, Zurich, Switzerland Lesley Ann Saketkoo New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, USA Tulane Lung Center, Tulane University School of Medicine, New Orleans, LA, USA University Medical Center, Comprehensive Pulmonary Hypertension Center, University Medical Center, New Orleans, LA, USA Abstract Pulmonary hypertension is a potentially fatal disease. Despite pharmacological
Pulmonary arterial hypertension: pathogenesis and clinical management. Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of pulmonary hypertension that primarily affects the pulmonary vasculature. In PAH, the pulmonary vasculature is dynamically obstructed by vasoconstriction, structurally obstructed by adverse vascular remodeling, and pathologically non-compliant as a result